Details for Patent: 9,732,092
✉ Email this page to a colleague
Which drugs does patent 9,732,092 protect, and when does it expire?
Patent 9,732,092 protects BIKTARVY and is included in one NDA.
This patent has one hundred and twenty-eight patent family members in thirty-nine countries.
Summary for Patent: 9,732,092
| Title: | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1',2':4,5]pyrazino[2,1-b][1,3]OXAZEPIN- ES and methods for treating viral infections |
| Abstract: | Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): ##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, X, W, Y.sup.1, Y.sup.2, Z.sup.1, and Z.sup.4 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. |
| Inventor(s): | Jin; Haolun (Foster City, CA), Lazerwith; Scott E. (Burlingame, CA), Pyun; Hyung-Jung (Fremont, CA), Bacon; Elizabeth M. (Burlingame, CA), Morganelli; Philip Anthony (Oakland, CA), Ji; Mingzhe (Union City, CA) |
| Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
| Application Number: | 15/349,934 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 9,732,092
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | BIKTARVY | bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210251-002 | Oct 7, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Gilead Sciences Inc | BIKTARVY | bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210251-001 | Feb 7, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,732,092
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2822954 | ⤷ Sign Up | 300947 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2822954 | ⤷ Sign Up | 122018000094 | Germany | ⤷ Sign Up |
| European Patent Office | 2822954 | ⤷ Sign Up | LUC00083 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2822954 | ⤷ Sign Up | CA 2018 00029 | Denmark | ⤷ Sign Up |
| European Patent Office | 2822954 | ⤷ Sign Up | PA2018511 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2822954 | ⤷ Sign Up | 33/2018 | Austria | ⤷ Sign Up |
| European Patent Office | 2822954 | ⤷ Sign Up | 2018C/031 | Belgium | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
